drugset
drugset / Trial / NCT00131937

Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

NCT00131937 ↗

Phase 2 Completed 14 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start
2005-10
Primary completion
2011-09
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral

Indications

adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma diffuse large B-cell lymphoma hepatosplenic T-cell lymphoma large-cell immunoblastic lymphoma peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma